Explore 3 Stock Ideas & Industry Insights Download Free Report

mid-cap

MSB Remains Loss-Making with Continued Negative Cash Flow

Jun 21, 2026 | Team Kalkine
MSB Remains Loss-Making with Continued Negative Cash Flow
Image source: shutterstock

  • MSB:ASX
  • Investment Type
    Mid - Cap
  • Risk Level
  • Action
  • Rec. Price (AU$)

This report is an updated version of the report published on 22 June 2026 at 11:25 AM AEST.

Mesoblast Limited (ASX: MSB)

Mesoblast Limited (ASX: MSB) is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. Using its proprietary mesenchymal lineage cell therapy technology platform, the company has established a broad portfolio of late-stage product candidates.


Disclaimer-

Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions  and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.

Past performance is not a reliable indicator of future performance.

Support

Hi! How can we help you today?

Loading…